Is this why ketamine helps with depression?
Perception study may explain promising depression therapy Our brains are constantly making predictions about the
January 31, 2022
Perception study may explain promising depression therapy Our brains are constantly making predictions about the
Debunking the myth of ‘Blue Mondays’: No evidence of affect drop after taking clinical MDMA
Psyched Wellness Provides Update on Anti-Inflammatory Study with the National Research Council of Canada The
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder MindMed’s LSD-based compound
Subjective effects of MDMA (‘Ecstasy’) on human sexual function Over 90% of people experienced increased
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke
Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin
Novamind Hosts Pioneering Psychedelic Clinical Trial for Opioid Use Disorder Novamind (NM) is hosting a
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
Wesana Health Granted US FDA Pre-IND Meeting for SANA-013 The majority of patients with traumatic
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC MindMed (MNMD) developed a non-hallucinogenic molecule
Mindset Pharma Announces Filing of International Patent Application Covering its Family 3 “Microdose” Compounds Here’s
Tryp Therapeutics: An Interview with Jim Gilligan Ph.D. Over-eating disorders occur when the brain is
Latest Trials Confirm the Benefits of MDMA – the Drug in Ecstasy – for Treating
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel HaluGen Life Sciences expanded its psychedelic DNA
Ixtlan Bioscience Announces the Filing of New Patent for the Psilocybin Treatment of Alzheimer’s Disease
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD MindMed (MNMD) is
Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome
B.C.’s functional and psychedelic mushroom industry is having a shroom boom Antidepressants are often ineffective
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical
Take Two Shrooms and Call Me in the Morning: The Medical Promise of Magic Mushrooms
Study suggests psychedelics promote positive mental health through increased spirituality and emotion regulation A recent